IDH1 and acute myeloid leukemia: The ongoing multicenter, randomized, phase III clinical trial, AGILE (NCT03173248), will determine the benefit of this approach by comparing azacitidine with or without ivosidenib in adult subjects with previously untreated IDH1-mutated AML not considered candidates for intensive therapy.